文献速递肝病

系统综述:肝硬化或酒精相关性肝炎患者酒精使用障碍的干预措施

Systematic review: Interventions for alcohol use disorder in patients with cirrhosis or alcohol-associated hepatitis.
PubMed 文献 · Aliment Pharmacol Ther · 2023-08-21

该系统综述检索五个数据库至2022年11月,纳入23项研究(6项随机试验和17项非随机研究),共104,298例患者。巴氯芬是唯一在随机试验中对主要结局显示统计学显著影响的干预(戒酒OR:6.3,95%CI:2.4-16.1)。非随机研究提示心理治疗、药物治疗等可能改善临床结局。

要点

  • 巴氯芬是唯一在随机试验中显示显著戒酒获益的干预(OR:6.3,95%CI:2.4-16.1)。
  • 三项非随机研究报告心理治疗、任何药物治疗或任何治疗可减少肝功能失代偿发作。
  • 非随机研究的Meta分析显示心理治疗对戒酒和死亡率的改善未达统计学显著。

核心结论

  • 巴氯芬是唯一在肝硬化患者中具有随机试验证据显示显著获益的干预措施。
  • 非随机研究也提示非药物干预可能改善临床结局。

研究设计与样本

  • 系统综述,检索五个数据库从建库至2022年11月。
  • 纳入6项随机试验和17项非随机研究,共104,298例患者,平均/中位年龄范围44至65岁,其中75%为男性。

主要发现

  • 巴氯芬在随机试验中对戒酒显示统计学显著影响(OR:6.3,95%CI:2.4-16.1)。
  • 三项非随机研究报告心理治疗、使用任何药物治疗和使用任何治疗可减少肝功能失代偿发作,在多变量模型中显著。
  • 非随机研究的Meta分析显示心理治疗对戒酒的改善未达统计学显著(4项研究,OR:1.87,95%CI:0.38-9.23)。
  • 非随机研究的Meta分析显示心理治疗对死亡率的改善未达统计学显著(4项研究,OR:0.47,95%CI:0.12-1.77)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Alcohol use is the most important factor in determining the prognosis of patients with alcohol-related cirrhosis and alcohol-associated hepatitis. AIM: To conduct a systematic review of interventions for alcohol use disorder specific to patients with cirrhosis or alcohol-associated hepatitis. METHODS: We searched five databases between inception and November 2022. The primary outcomes were abstinence, hepatic decompensation and mortality. We included randomised and non-randomised studies. Risk of bias was assessed using validated tools. Where possible, meta-analysis was performed. RESULTS: Twenty-three studies met the inclusion criteria including six randomised trials and 17 non-randomised studies of interventions. These included 104,298 patients with a mean/median age range from 44 to 65, of whom 75% were male. Interventions included psychological therapy, pharmacological therapies, specialist clinics, patient education and low alcohol drinks. Baclofen was the only intervention to demonstrate a statistically significant impact on the primary outcomes in a randomised trial (abstinence OR: 6.3, 95% CI: 2.4-16.1). Three non-randomised studies reported reductions in episodes of hepatic decompensation that were significant in multivariate models. This was in response to psychological therapy, use of any pharmacotherapy, and use of any treatment. A meta-analysis of non-randomised studies that examined the impact of psychological therapies revealed statistically non-significant improvements in abstinence (4 studies, OR: 1.87, 95% CI: 0.38-9.23) and mortality (4 studies, OR: 0.47, 95% CI: 0.12-1.77). CONCLUSIONS: Baclofen is the only intervention with randomised trial evidence for significant benefit in patients with cirrhosis. Non-randomised studies also point to non-pharmaceutical interventions possibly improving clinical outcomes.

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Oldroyd C, Greenham O, Martin G, et al. Systematic review: Interventions for alcohol use disorder in patients with cirrhosis or alcohol-associated hepatitis. Aliment Pharmacol Ther. 2023. PMID: 37602505. doi:10.1111/apt.17665

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。